Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The hemagglutinin (HA) protein is a homotrimeric, class I fusion glycoprotein found on the surface of influenza A viruses, specifically the H7 subtype. It is the most abundant transmembrane protein on the viral envelope and plays a central role in virus infectivity and host specificity. HA binds to sialic acid-containing receptors on host cell surfaces and mediates fusion between viral and cellular membranes—an essential step for viral genome release into the cytoplasm. Antigenic variation occurs frequently, complicating vaccine design. H7 viruses have caused outbreaks in poultry worldwide and sporadic human infections with pandemic potential due to their ability to adapt across species barriers. It is an attractive target for antiviral drugs and broadly protective vaccines.
Inhibition of receptor binding or membrane fusion
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza A Virus Hemagglutinin Protein (H7).